Limits...
Decreased brain-derived neurotrophic factor plasma levels in psoriasis patients.

Brunoni AR, Lotufo PA, Sabbag C, Goulart AC, Santos IS, Benseñor IM - Braz. J. Med. Biol. Res. (2015)

Bottom Line: Brain-derived neurotrophic factor (BDNF) is associated with neuroplasticity and synaptic strength, and is decreased in conditions associated with chronic stress.Participants had neither a previous history of coronary artery disease nor current episode of major depression.Similar BDNF levels were found in both mild and severe cases of psoriasis.

View Article: PubMed Central - PubMed

Affiliation: Centro de Pesquisa Clínica e Epidemiológica, Hospital das Clínicas, Universidade de São Paulo, São Paulo, SP, Brasil.

ABSTRACT
Brain-derived neurotrophic factor (BDNF) is associated with neuroplasticity and synaptic strength, and is decreased in conditions associated with chronic stress. Nevertheless, BDNF has not yet been investigated in psoriasis, a chronic inflammatory systemic disease that is exacerbated by stress. Therefore, our aim was to determine BDNF plasma levels in psoriasis patients and healthy controls. Adult patients (n=94) presenting with psoriasis for at least 1 year were enrolled, and age- and gender-matched with healthy controls (n=307) from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Participants had neither a previous history of coronary artery disease nor current episode of major depression. BDNF plasma levels were determined using the Promega ELISA kit. A general linear model was used to compare BDNF levels in psoriasis patients and controls, with age, gender, systolic blood pressure, serum fasting glucose, blood lipid levels, triglycerides, smoking status, and body mass index examined. After adjusting for clinical and demographic variables, significantly decreased BNDF plasma levels were observed in psoriasis patients (P=0.01) (estimated marginal means of 3922 pg/mL; 95%CI=2660-5135) compared with controls (5788 pg/mL; 95%CI=5185-6442). Similar BDNF levels were found in both mild and severe cases of psoriasis. Our finding, that BDNF is decreased in psoriasis, supports the concept of a brain-skin connection in psoriasis. Further studies should determine if BDNF is increased after specific psoriasis treatments, and associated with different disease stages.

No MeSH data available.


Related in: MedlinePlus

Brain-derived neurotrophic factor (BDNF) plasma levels in psoriasispatients (n=94) and controls (n=307). Data are reported as mean plasma BDNF and95%CI upper limit. P≤0.01, psoriasis patients compared to controls(t-test).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4541690&req=5

f01: Brain-derived neurotrophic factor (BDNF) plasma levels in psoriasispatients (n=94) and controls (n=307). Data are reported as mean plasma BDNF and95%CI upper limit. P≤0.01, psoriasis patients compared to controls(t-test).

Mentions: Although similar in age and gender, psoriasis patients had higher BMI, SBP, HDLc,LDLc, and triglyceride levels compared with controls (Table 1). Additionally, BDNF plasma levels were significantlydifferent between groups (P<0.01), being lower in psoriasis patients (Figure 1). The multivariate model (with allvariables in Table 1 introduced aspredictors) showed that BDNF levels remained significantly lower in psoriasispatients (P=0.01) (estimated marginal means of 3922 pg/mL; 95%CI=2660-5135) comparedwith controls (5788 pg/mL; 95%CI=5185-6442).


Decreased brain-derived neurotrophic factor plasma levels in psoriasis patients.

Brunoni AR, Lotufo PA, Sabbag C, Goulart AC, Santos IS, Benseñor IM - Braz. J. Med. Biol. Res. (2015)

Brain-derived neurotrophic factor (BDNF) plasma levels in psoriasispatients (n=94) and controls (n=307). Data are reported as mean plasma BDNF and95%CI upper limit. P≤0.01, psoriasis patients compared to controls(t-test).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4541690&req=5

f01: Brain-derived neurotrophic factor (BDNF) plasma levels in psoriasispatients (n=94) and controls (n=307). Data are reported as mean plasma BDNF and95%CI upper limit. P≤0.01, psoriasis patients compared to controls(t-test).
Mentions: Although similar in age and gender, psoriasis patients had higher BMI, SBP, HDLc,LDLc, and triglyceride levels compared with controls (Table 1). Additionally, BDNF plasma levels were significantlydifferent between groups (P<0.01), being lower in psoriasis patients (Figure 1). The multivariate model (with allvariables in Table 1 introduced aspredictors) showed that BDNF levels remained significantly lower in psoriasispatients (P=0.01) (estimated marginal means of 3922 pg/mL; 95%CI=2660-5135) comparedwith controls (5788 pg/mL; 95%CI=5185-6442).

Bottom Line: Brain-derived neurotrophic factor (BDNF) is associated with neuroplasticity and synaptic strength, and is decreased in conditions associated with chronic stress.Participants had neither a previous history of coronary artery disease nor current episode of major depression.Similar BDNF levels were found in both mild and severe cases of psoriasis.

View Article: PubMed Central - PubMed

Affiliation: Centro de Pesquisa Clínica e Epidemiológica, Hospital das Clínicas, Universidade de São Paulo, São Paulo, SP, Brasil.

ABSTRACT
Brain-derived neurotrophic factor (BDNF) is associated with neuroplasticity and synaptic strength, and is decreased in conditions associated with chronic stress. Nevertheless, BDNF has not yet been investigated in psoriasis, a chronic inflammatory systemic disease that is exacerbated by stress. Therefore, our aim was to determine BDNF plasma levels in psoriasis patients and healthy controls. Adult patients (n=94) presenting with psoriasis for at least 1 year were enrolled, and age- and gender-matched with healthy controls (n=307) from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Participants had neither a previous history of coronary artery disease nor current episode of major depression. BDNF plasma levels were determined using the Promega ELISA kit. A general linear model was used to compare BDNF levels in psoriasis patients and controls, with age, gender, systolic blood pressure, serum fasting glucose, blood lipid levels, triglycerides, smoking status, and body mass index examined. After adjusting for clinical and demographic variables, significantly decreased BNDF plasma levels were observed in psoriasis patients (P=0.01) (estimated marginal means of 3922 pg/mL; 95%CI=2660-5135) compared with controls (5788 pg/mL; 95%CI=5185-6442). Similar BDNF levels were found in both mild and severe cases of psoriasis. Our finding, that BDNF is decreased in psoriasis, supports the concept of a brain-skin connection in psoriasis. Further studies should determine if BDNF is increased after specific psoriasis treatments, and associated with different disease stages.

No MeSH data available.


Related in: MedlinePlus